Ardelyx, Inc.
ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

Last updated:

Abstract:

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): ##STR00001## wherein L.sub.1, L.sub.2, A, B, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are described herein.

Status:
Application
Type:

Utility

Filling date:

7 Apr 2021

Issue date:

30 Sep 2021